GP
NVET

GLG Partners’s Nexvet Biopharma plc Ordinary Shares NVET Stock Holding History

GLG Partners’s Portfolio NVET Stock Details NVET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-60,098
Closed -$402K – 405
2017
Q2 		$402K Buy
+60,098
New +$378K 0.02% 281

GLG Partners's NVET Position: Q3 2017 in Review

GLG Partners sold out of Nexvet Biopharma plc Ordinary Shares (NVET) in Q3 2017, closing a stake of 60,098 shares — an estimated $402K sold.

GLG Partners first reported a position in NVET in Q2 2017 and held it in 1 quarter. The position peaked at $402K in Q2 2017. 0 funds tracked by Wall St. Rank hold NVET as of Q3 2017.

  • GLG Partners reported no remaining Nexvet Biopharma plc Ordinary Shares position as of Q3 2017 after selling out during the quarter.
  • GLG Partners sold 60,098 Nexvet Biopharma plc Ordinary Shares shares in Q3 2017, an estimated $402K.
  • GLG Partners first reported a position in Nexvet Biopharma plc Ordinary Shares in Q2 2017 and held it in 1 quarter.
  • GLG Partners's Nexvet Biopharma plc Ordinary Shares position peaked at $402K in Q2 2017.
  • 0 funds tracked by Wall St. Rank held Nexvet Biopharma plc Ordinary Shares as of Q3 2017.

Based on GLG Partners's 13F filing for Q3 2017, filed 14 Nov 2017.